HonCode

Go Back   HER2 Support Group Forums > General Cancer News
Reload this Page FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prosta
Register Gallery FAQ Members List Calendar Today's Posts

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply
 
Thread Tools Display Modes
Old 12-30-2011, 01:02 AM   #1
News
Senior Member
 
News's Avatar
 
Join Date: Oct 2007
Posts: 19,725
FDA invites Amgen for ODAC meeting on XGEVA sBLA to treat castration-resistant prosta
Amgen today announced the U.S. Food and Drug Administration has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

More...
News is offline   Reply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 10:02 PM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter